Thu, Oct 23, 2014, 6:31 AM EDT - U.S. Markets open in 2 hrs 59 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • qdelfan qdelfan May 3, 2013 11:35 PM Flag

    Update from S&P May 1

    May 1, 2013
    11:11 am ET ... S&P MAINTAINS BUY OPINION ON SHARES OF VERTEX
    PHARMACEUTICALS (VRTX 78.02****):We keep our target price at $100. Q1
    adjusted loss of $0.10, vs. $0.43 EPS inclusive of stock option expense, is
    narrower than our $0.16 loss view, on higher revenues. However, sales declined
    25% due to waning Incivek demand ahead of new expected hepatitis C entrants.
    We narrow our '13 adjusted loss forecast $0.06 to a $0.77 loss.We remain
    confident in VRTX's cystic fibrosis program, with key F508del mutation sub-group
    on track for '14 FDA filing. With $1.24B in cash, we think VRTX is on solid financial
    footing to invest in its pipeline for long-term growth. /S.Silver

 
VRTX
106.17-1.99(-1.84%)Oct 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.